Module 9 Quiz

A  Human cells

B  All cell types

C  Bacterial cells

D  Fungal cells

A  Structure of chromosomes

B  Presence of double-stranded DNA

C  Number of chromosomes

D  Number of genes

A  unwinding and separating the double-stranded DNA.

B  binding of the primers to the single-stranded DNA.

C  adding nucleotides to primed sites of the DNA strands.

D  making a cDNA from an mRNA strand.

A  Deletion of a deoxyribonucleotide

B  Addition of a deoxyribonucleotide

C  Addition of a dideoxynucleotide

D  Addition of a ribonucleotide

A  Blank control

B  dTTP control

C  Oligoligated control

D  Positive control

A  Lysozyme

B  Restriction enzyme

C  Polymerase

D  Transcriptase

A  sequence of nucleotides that codes for a protein.

B  sequence of three nucleotides.

C  phosphate group, a ribose sugar, and nitrogen.

D  polymeric molecule composed of nucleic acids.

A  Hydrogen

B  Phosphate group

C  Methyl group

D  Hydroxyl group

A  histones.

B  nucleotides.

C  hormones.

D  lysosomes.

A  40%

B  60%

C  30%

D  20%

A  toxidrome.

B  toxin effect.

C  metabolic pattern.

D  pattern constellation.

A  HPLC.

B  spectrophotometry.

C  immunoassay.

D  flame ionization gas chromatography (GC).

A  The myocardial infarction is caused by the effect on respiratory centers in the brain and eventual lack of stimulation of the heart.

B  The metabolic acidosis produced is caused by increased formation of formic acid by the liver during metabolism.

C  The hepatic necrosis is caused by depletion of a substance in the liver and eventual accumulation of the oxidized metabolite.

D  The coma produced is caused by an immediate decrease in sensitivity to CO2 concentration through depression of respiratory centers in the brain.

A  [Na+] − [Cl− +  [HCO3-]

B  [HCO3-]  − [Na+ + Cl−].

C  [Na+] + [Cl− +  [HCO3-]

D  [Cl−] + [Na+ +  [HCO3-]

A  GC-MS.

B  a more sensitive and specific immunoassay procedure.

C  electrophoresis.

D  a spot test.

A  There is no specific time that is the best for blood collection.

B  At 8 AM, when liver metabolism is highest.

C  Immediately after a dose of the drug is given.

D  Immediately before a dose of the drug is given.

A  To monitor significant drug-drug interactions

B  To monitor drugs with a broad therapeutic range

C  To check patient compliance

D  To determine drug concentrations in a pathophysiological state

A  Using a single drug as opposed to multiple drugs for treatment

B  Decreased renal elimination leading to increased free drug concentration

C  Using a different route of administration than is typically used for that drug

D  Increased drug metabolism caused by central nervous system disease

A  Albumin

B  Albumin, Lipoprotein, and α1-Glycoprotein

C  α1-Glycoprotein

D  Lipoprotein

A  dosing curve.

B  volume of distribution.

C  half-life.

D  subtherapeutic range.